Maintaining quality of life for patients with neuroendocrine tumours
Mené dans 25 pays sur 302 patients atteints d'une tumeur neuro-endocrine gastro-intestinale ou pulmonaire bien différenciée de stade avancé, cet essai de phase III évalue les effets de l'évérolimus sur la qualité de vie
Ideally, new treatments should either improve overall survival or the health-related quality of life (HRQOL) of patients, or both, and should have a favourable cost-to-benefit ratio. For instance, FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) significantly improves progression-free survival, overall survival, and HRQOL compared with gemcitabine in patients with metastatic pancreatic adenocarcinoma, even though it causes substantially more side-effects.1,2 After publication of the RADIANT-3 and RADIANT-4 randomised, placebo-controlled, phase 3 studies, everolimus was approved for all non-functional, advanced, neuroendocrine tumours (NETs), including those of the pancreas,3 lung, and gastrointestinal tract,4 and sunitinib has been approved for pancreatic NETs (pNETs).
The Lancet Oncology , commentaire, 2016